The US has exempted Indian pharmaceuticals from tariffs amidst President Trump’s broad tariff imposition, recognizing their crucial role in global healthcare. This move reinforces India’s position as a key provider of affordable generic medicines. Leaders highlight the strategic importance of the bilateral trade relationship, with the exemption offering India a chance to enhance its pharmaceutical sector. Post navigation India Inc anticipates limited impact from US tariffs, foresees global trade realignment Fab 5: The five countries missing from Trump’s list of reciprocal tariffs
